Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 38.1% on Thursday . The company traded as high as C$0.15 and last traded at C$0.15. 605,625 shares traded hands during mid-day trading, an increase of 51% from the average session volume of 401,760 shares. The stock had previously closed at C$0.11.
Hemostemix Price Performance
The company has a fifty day moving average of C$0.09 and a 200-day moving average of C$0.07. The firm has a market capitalization of C$12.63 million, a PE ratio of -7.25 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Insider Buying Explained: What Investors Need to Know
- Warren Buffett Bets on the Digital Economy With New VeriSign Buy
- P/E Ratio Calculation: How to Assess Stocks
- Discover 2 Under-the-Radar Aerospace Stocks Set for 2025 Growth
- Market Cap Calculator: How to Calculate Market Cap
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
